Copyright
©The Author(s) 2019.
World J Gastroenterol. Apr 14, 2019; 25(14): 1684-1696
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Published online Apr 14, 2019. doi: 10.3748/wjg.v25.i14.1684
Figure 4 Programmed death ligand 1 copy number is associated with programmed death ligand 1 expression in gastric neuroendocrine carcinomas.
A: Programmed death ligand 1 (PD-L1) copy number status varied in 19 gastric neuroendocrine carcinoma samples. The cases with copy number gain are shown in black; B: Cases with copy number gain showed significantly higher PD-L1 expression than those without. PD-L1: Programmed death ligand 1.
- Citation: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696
- URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i14.1684